8-KOther EventsExhibits & Filings

Elevance Health, Inc. 8-K Report, Corporate Update (Nov 29, 2017)

Filed November 29, 2017For Securities:ELV

Summary

Elevance Health, Inc. (operating as Anthem, Inc. at the time of this filing) announced the completion and pricing of its previously disclosed cash tender offer for its outstanding notes. This "Maximum Tender Offer" aimed to repurchase up to a specified aggregate principal amount of various senior notes, including those due in 2037, 2034, 2036, 2040, and 2044. The press releases attached as exhibits detail the results and pricing, providing investors with transparency on the company's debt management activities. This action indicates a proactive approach by management to manage its capital structure and potentially optimize its cost of debt. Investors should note that such tender offers can signal confidence in the company's financial health and its ability to refinance or manage its obligations efficiently. The specifics of the pricing and the principal amounts accepted will influence the company's future interest expenses and cash flow obligations.

Key Highlights

  • 1Anthem, Inc. (Elevance Health) announced the results and pricing of a significant cash tender offer for its outstanding senior notes.
  • 2The tender offer encompassed multiple series of notes with varying maturity dates and interest rates.
  • 3The company aimed to repurchase up to an aggregate principal amount of $836.347 million of its outstanding notes, an amount that had been previously increased.
  • 4The tender offer was conducted under the terms outlined in the offer to purchase dated November 14, 2017.
  • 5The filing includes two press releases detailing the results and pricing of the Maximum Tender Offer.
  • 6This action suggests proactive debt management and potential optimization of the company's capital structure.

Frequently Asked Questions

The primary purpose of this tender offer was for Anthem, Inc. (Elevance Health) to repurchase a portion of its outstanding senior notes. This is a common strategy for companies to manage their debt profile, potentially reduce interest expenses, and optimize their capital structure.

The tender offer involved several series of the company's outstanding senior notes: 6.375% Notes due 2037, 5.950% Notes due 2034, 5.850% Notes due 2036, 5.800% Notes due 2040, and 5.100% Notes due 2044.

The company intended to repurchase up to an aggregate principal amount of $836.347 million of its outstanding notes. This amount was previously increased, indicating a substantial commitment to this debt management strategy.

More details about the results and pricing of the Maximum Tender Offer can be found in the two press releases attached as Exhibits 99.1 and 99.2 to this Form 8-K filing.